|1.||Sulzbacher, Irene: 4 articles (12/2010 - 01/2003)|
|2.||Kazlauskas, Andrius: 4 articles (05/2010 - 02/2002)|
|3.||Schimanski, Carl C: 4 articles (03/2010 - 03/2008)|
|4.||Gockel, Ines: 4 articles (03/2010 - 03/2008)|
|5.||Moehler, Markus: 4 articles (03/2010 - 03/2008)|
|6.||Galle, Peter R: 4 articles (03/2010 - 03/2008)|
|7.||Loizos, Nick: 4 articles (02/2010 - 03/2005)|
|8.||van Zoelen, Everardus J J: 4 articles (07/2009 - 12/2002)|
|9.||Toepoel, Mascha: 4 articles (07/2009 - 12/2002)|
|10.||Nistér, M: 4 articles (08/2006 - 11/2000)|
09/01/2010 - "Daily treatment of 6-month-old DEN-exposed beta-cat KO with PDGFRalpha inhibitor dramatically reduced tumor numbers and size. "
03/01/2005 - "These data suggest that 3G3 may be useful for the treatment of tumors that express PDGFRalpha."
11/01/2009 - "Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFRalpha/KIT inhibitors."
04/01/2009 - "These studies demonstrate that combined inhibition of PDGFRalpha and -beta results in markedly decreased tumor growth in vivo because of impaired recruitment of periendothelial cells."
07/01/2011 - "The present review evaluates the most important parameters in GIST: epidemiology, principal clinical presentations, histopathological patterns of GIST with differential diagnosis and Fletcher's and Miettinen's risk classification, immunohistochemistry, prognostic factors, c-KIT and PDGFRalpha mutations and treatment of this tumor. "
|2.||Hypereosinophilic Syndrome (Loeffler Endocarditis)
11/01/2009 - "The pathogenesis of hypereosinophilic syndrome (HES) in some patients is highly dependent on FIP1-Like-1 (FIP1L1)-platelet-derived growth factor receptor alpha (PDGFRalpha), which can generate sustained activation signaling to maintain a cell malignant phenotype. "
11/01/2008 - "[FIP1L1/PDGFRalpha fusion gene-negative chronic eosinophilic leukemia with t(5;12)(q31;p13): a case report and review of literatures]."
09/15/2008 - "FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome."
11/12/2006 - "The diagnosis of chronic myeloid leukemia and certain types of chronic eosinophilic leukemia are based on the detection of fusion genes (in chronic myeloid leukemia the BCR/ABL fusion gene, and in chronic eosinophilic leukemia the FIP1L1-PDGFRalpha gene). "
04/01/2008 - "PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment."
10/26/2005 - "Moreover, thermal hyperalgesia and tactile allodynia induced by thrombin in normal mice were virtually eliminated by intrathecal pretreatment with PDGFRalpha/Fc. "
10/26/2005 - "Thermal hyperalgesia and tactile allodynia induced by sciatic nerve ligation were also suppressed by repeated intrathecal injection of either the PDGF alpha receptor (PDGFRalpha)/Fc chimera protein or the PDGFR-dependent tyrosine kinase inhibitor AG17 [(3,5-di-tert-butyl-4-hydroxybenzylidene)-malononitrile]. "
|4.||Prostatic Neoplasms (Prostate Cancer)
05/15/2010 - "Our studies show that this truncated PDGFRalpha is able to restore bone-metastatic potential of prostate cancer cells as effectively as the full-length form of the receptor."
01/22/2009 - "Finally, functional blockade of human PDGFRalpha on prostate cancer cells utilizing a novel humanized monoclonal antibody -- soon to undergo phase-II clinical trials -- significantly impairs the establishment of early skeletal metastases. "
01/22/2009 - "Interestingly, prostate cancer cells expressing the alpha-receptor for platelet-derived growth factor (PDGFRalpha) progress during early-stages of skeletal dissemination, whereas cells expressing lower levels or lacking this receptor fail to survive after extravasation in the bone marrow. "
01/22/2009 - "In conclusion, our results strongly implicate PDGFRalpha in prostate cancer bone tropism through its promotion of survival and progression of early-metastatic foci, providing ground for therapeutic strategies aimed at preventing or containing the initial progression of skeletal metastases in patients affected by prostate adenocarcinoma."
05/15/2010 - "We previously showed that bone-metastatic prostate cancer cells exposed to human bone marrow respond by activation of cell survival pathways, such as phosphoinositide 3-kinase/Akt, and that these events are mediated by the alpha-receptor for platelet-derived growth factor (PDGFRalpha). "
04/01/2006 - "PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma."
12/01/2001 - "Because PDGF-alpha receptor expression positively correlates with the aggressiveness of chondrosarcoma, it may be considered as a possible target for novel therapeutic strategies."
12/01/2001 - "Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome."
12/01/2001 - "PDGF-alpha receptor expression was significantly higher in grade 3 chondrosarcomas compared with grade 2 (p = 0.022) and grade 1 tumors (p = 0.002). "
12/01/2001 - "In this study we wanted to determine the expression of PDGF-AA and PDGF-alpha receptor in conventional chondrosarcomas and to compare the results with those obtained from benign enchondromas and non-neoplastic cartilage tissue. "
|3.||Platelet-Derived Growth Factor
|6.||Transforming Growth Factors (Transforming Growth Factor)
|7.||Insulin-Like Growth Factor II (Somatomedin A)
|8.||platelet-derived growth factor AB
|10.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|2.||Drug Therapy (Chemotherapy)
|3.||Homologous Transplantation (Allograft)